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Summary
Several studies support the relation between leptin and Alzhei-
mer’s disease (AD). We show that leptin levels in CSF are
unchanged as subjects progress to AD. However, in AD hippocam-
pus, leptin signalling was decreased and leptin localization was
shifted, being more abundant in reactive astrocytes and less in
neurons. Similar translocation of leptin was found in brains from
Tg2576 and apoE4 mice. Moreover, an enhancement of leptin
receptors was found in hippocampus of young Tg2576mice and in
primaryastrocytes andneurons treatedwithAb1-42. In contrast, old
Tg2576 mice showed decreased leptin receptors levels. Similar
findings to those seen in Tg2576micewere found in apoE4, but not
in apoE3 mice. These results suggest that leptin levels are intact,
but leptin signalling is impaired in AD. Thus, Ab accumulation and
apoE4 genotype result in a transient enhancement of leptin
signalling that might lead to a leptin resistance state over time.
Key words: Alzheimer’s disease; amyloid-beta; ApoE geno-
type; CSF; leptin receptors; leptin.
Introduction
The hormone leptin is mainly synthesized by adipocytes and circulates in
the plasma in proportion to fat mass (Klein et al., 1996). Leptin acts as a
regulator of body energy expenditure and food intake (Elmquist et al.,
1998). Circulating leptin is taken into the brain, across the blood brain
barrier (BBB), where its main action is in the hypothalamus. However,
leptin receptors (LepR) are widely expressed in other brains regions
including the hippocampus. Accumulating evidence from cell and animal
models shows positive effects on memory processes and neuroprotec-
tion (Shanley et al., 2001; Harvey et al., 2006; Guo et al., 2008). In
addition, leptin presents various functions in the immune system,
including inflammation (Paz-Filho et al., 2013), and plays a major role in
the chronic pro-inflammatory state that is seen in obesity and athero-
sclerosis (Conde et al., 2011).
An increasing number of epidemiological and experimental studies
provide support for the link between leptin and Alzheimer’s disease (AD)
pathogenesis. Circulating levels of leptin were reported to be signifi-
cantly lower in patients with AD as compared to controls (Power et al.,
2001). Recently, Lieb et al. reported that high plasma concentrations of
leptin correlate with a significantly lower risk of AD, larger cerebral brain
and hippocampal volumes (Lieb et al., 2009). In contrast, Rajagopalan
et al. showed that high leptin levels in plasma correlate with volume loss
in several brain regions, regardless of clinical diagnosis or body mass
index (BMI) (Rajagopalan et al., 2012). Another recent study reported
significant elevation in leptin levels in both CSF and hippocampus of
patients with AD (Bonda et al., 2013). The importance of leptin in AD is
suggested by several studies. In vitro, leptin treatment is reported to
reduce Ab levels in neurons by inhibiting b-secretase activity and to
reduce tau phosphorylation through the modulation of tau kinases
(Greco et al., 2008, 2009). Leptin treatment of murine models of AD
resulted in significant reductions of Ab, phosphorylated Tau (p-tau) and
cognitive deficits (Greco et al., 2010). Based on this, the possibility of a
potential use of leptin as a replacement therapy in the treatment of AD
has been proposed.
The aims of this study were to (A) clarify whether brain leptin levels
are affected during the progression of AD, (B) investigate the
relationship between CSF leptin levels and hippocampal volume, AD
biomarkers, such as Ab, total-tau (t-tau), phospho-tau (p-tau) and
inflammatory markers. In addition, the cellular localization and distri-
bution of leptin and leptin receptors (LepR) were studied in hippocam-
pus and frontal cortex from patients with AD and control individuals, as
well as in mice models of relevance for AD pathology (Tg2576, apoE4
and apoE3). Finally, (C) the possible effects of Ab on leptin and LepR
signalling were also investigated in primary astrocyte and neuronal cell
cultures.
Results
CSF leptin levels in the ADNI cohort study
The results of one-way ANOVA analysis for age, education, leptin levels,
interleukin-6 receptors (IL-6R) and interleukin-3 (IL-3) in CSF revealed no
significant differences between the four diagnostic groups (AD, MCI-c,
MCI-s and CTL). The mean MMSE, hippocampal volume, Ab1-42, t-tau
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and p-tau CSF levels were significantly different (P < 0.001) between the
diagnostic groups (Table 1).
Table 2 shows the results of bivariate correlation between pairs of
leptin, hippocampal volume, Ab1-42, t-tau, p-tau, IL-6R and IL-3 for the
entire cohort and also for only CTL and MCI subjects. In the entire
cohort, significant correlations were observed between leptin and
hippocampal volume (Pearson coef. = 0.155, P = 0.009), between
leptin and IL-6R (Pearson coef. = 0.121, P = 0.043), and between
leptin and IL-3 (Pearson coef. = 0.125, P = 0.037). In particular,
correlations between leptin and hippocampus were investigated with
regard to age, education, gender and apoE4 genotype. A linear
regression model was used to adjust for the effect of age, education,
gender and apoE genotype (E4 carriers vs. noncarriers) on the correla-
tion. Table 3 shows the result of the linear regression model. After
adjustments, the correlation between leptin and hippocampal volume
was not significant. According to the regression model, the observed
correlation between leptin and hippocampal volume was due to gender
variations. Further testing by means of independent sample t-test
highlighted that both leptin and hippocampal volume are significantly
different between female (higher) and male (lower) subjects (see
supplementary data, Table S2 and Figure S1).
Alterations in leptin and leptin signalling in AD brains
Pyramidal neurons, granular neurons and reactive astrocytes were
immunoreactive for leptin in hippocampus sections from controls and
AD (Fig. 1A, I–VI). In frontal cortex sections from the same individuals, a
similar staining pattern of leptin in pyramidal neurons and astrocytes
was observed (Fig. 1A, VII–XII). In the hippocampus of control brains,
the number of neurons immunopositive for leptin was significantly
higher than in AD brains (P = 0.015). In contrast, in the hippocampus of
AD brains, leptin staining was mainly present in reactive astrocytes,
being the number of reactive astrocytes immunopositive for leptin
significantly higher than controls (P = 0.028). In cortex, no differences
were found between AD and controls; however, in AD cortex, high
leptin signal inside some neurons, morphologically resembling tau-
bearing or ‘ghost’ neurons (Fig. 1A, X), was seen. Double immuno-
staining leptin/p-tau experiments revealed that this was not the case
(data not shown).
Levels of p-LepR (activated LepR), LepR and p-STAT3 (as additional
indicator of LepR activity) were analysed in hippocampal samples by
immunoblotting. As shown in Fig. 1B, the immunoblotting pattern of p-
LepR showed two major bands (at approximately 110 and 70 kDa),
corresponding with the long and the short isoforms of LepR (Ebenbichler
et al., 2002). The immunoreactivity of both p-LepR forms was decreased
in AD brains compared to controls (P = 0.008 and P = 0.03, respectively,
for 70 and 110 kDa). LepR and p-STAT3 levels were also significantly
decreased in hippocampus of AD subjects when compared to controls
(Fig. 1B; P = 0.01, P = 0.0004, respectively).
Changes in leptin localization and leptin receptor expression
in the brain of Tg2576 and apoE4 mice
Immunofluorescence for leptin was performed in brains of young and
old Tg2576 mice. Neurons and reactive astrocytes were immunoreactive
for leptin in hippocampal sections from Wt and Tg2576 (Fig. 2A). In old
Table 1 Study cohort
Healthy controls N = 88 MCI stable N = 81 MCI converters N = 46 Alzheimer’s disease N = 63 ANOVA P-value
Gender (Female/Male) 42/46 27/54 18/28 28/35
Age 75.8  5.5 74.1  7.0 75.3  7.0 74.4  7.6 0.369
Education 15.6  3.0 16.2  3.0 15.8  2.7 15.1  2.9 0.139
MMSE score 29.1  1.0 27.1  1.7 26.3  1.8 23. 5  1.8 <0.001
Nr. of APOE4 alleles (0/1/2) 66/20/2 41/31/9 16/21/9 18/30/15
Hippocampal volume 0.00280  0.00034 0.00237  0.00037 0.00216  0.00034 0.00219  0.00041 <0.001
Leptin 17.0  2.5 16.5  2.5 16.1  2.6 17.1  2.4 0.128
IL6R 5.05  0.14 5.06  0.15 5.02  0.14 5.03  0.13 0.420
IL3 8.5  1.8 8.4  1.9 8.0  2.0 7.9  1.9 0.173
P-Tau 24.9  13.2 34.7  16.4 39.9  15.2 43.3  20.4 <0.001
Ab1-42 206  57 164  55 146  39 138  31 <0.001
T-Tau 69  28 101  53 111  50 130  60 <0.001
Data are represented as mean  standard deviation. Education and age given in years. MMSE = Mini Mental State Examination. Hippocampus volume is normalized to
intracranial volume.
Table 2 The results of bivariate correlation between CSF leptin, hippocampal voulme and other CSF biomarkers
Leptin Hippo campal volume P-TAU Ab1-42 T-TAU IL-6R IL-3
Leptin 0.155 (0.009) 0.084 (0.160) 0.051 (0.393) 0.052 (0.392) 0.121 (0.043) 0.125 (0.037)
Hippocampal volume 0.260 (<0.001) 0.243 (<0.001) 0.311 (<0.001) 0.230 (<0.001) 0.007 (0.910) 0.005 (0.940)
P-TAU 0.075 (0.272) 0.245 (<0.001) 0.474 (<0.001) 0.771 (<0.001) 0.184 (0.002) 0.026 (0.669)
Ab1-42 0.076 (0.265) 0.271 (<0.001) 0.504 (<0.001) 0.403 (<0.001) 0.068 (0.261) 0.212 (<0.001)
T-TAU 0.065 (0.342) 0.198 (0.004) 0.759 (<0.001) 0.409 (<0.001) 0.261 (<0.001) 0.087 (0.147)
IL-6R 0.179 (0.008) 0.013 (0.845) 0.233 (0.001) 0.040 (0.559) 0.277 (<0.001) 0.413 (<0.001)
IL-3 0.061 (0.370) 0.053 (0.442) 0.029 (0.669) 0.198 (0.004) 0.094 (0.172) 0.432 (<0.001)
The upper-right triangle represents the results of bivariate correlation using data from all subjects, and the lower-left triangle (italic values) represents the correlations using
only HC and MCI subjects. Data are represented as Pearson correlation coefficients (P-value).
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Tg2576 animals, leptin immunoreactivity was significantly decreased in
neurons as compared to Wt old animals (P = 0.018). An increase in the
number of astrocytes immunopositive for leptin was also found in old
transgenic animals as compared to Wt old animals and to Tg young
animals (P = 0.026) (Fig. 2A).
We analysed the expression of LepR in Tg2576 mice hippocampus by
RT–PCR. As shown in Fig. 2B, a significant decrease in LepR expression in
old Tg2576 mice compared to age-matched controls (P = 0.05) was
found. Further, a trend was observed towards an increase in LepR
expression in young Tg2576 mice compared to Wt animals.
We further investigated the possibility that Ab1-42 could induce leptin
expression or alter the expression of LepR in brain cells. No expression of
leptin was found in brain samples from Wt and Tg2576 mice or in
astrocyte and hippocampal neuronal rat primary cultures even after Ab1-
42 treatment. As shown in Fig. 2C, a significant increase in LepR
expression was found after 24 h of 0.5 lM Ab1-42 treatment in both
astrocytes and hippocampal neurons as compared to controls (CTL) but
no effect of beta amyloid 1-42 scrambled (Abscr) on LepR expression was
observed (Fig. 2C; P < 0.001 CTL vs Ab1-42, P < 0.001 Abscr vs Ab1-42
for both neurons and astrocytes).
The above results suggest that changes in leptin or leptin signalling
observed in AD and Tg2576 mice brains might be mainly due to Ab
accumulation. Thus, another animal model of relevance for AD but
without Ab overproduction was studied (human apoE4 and apoE3 target
replacement mice). ApoE4 mice show cognitive impairment (Grooten-
dorst et al., 2005), and the apoE4 genotype is the strongest genetic risk
factor for developing AD (Cedazo-Minguez, 2007). As seen in Fig. 2D,
neurons and reactive astrocytes were immunoreactive for leptin in
hippocampus (CA1) and enthorinal cortex (EC) from both apoE3 and
apoE4 mice. In apoE4 mice, the number of astrocytes immunopositive
for leptin was significantly higher as compared to apoE3 mice
(P = 0.056). In contrast, the number of neurons immunopositive for
leptin was significantly decreased as compared to apoE3 (P = 0.012).
When LepR expression was analysed in the hippocampus of ApoE4 mice,
a similar result to Tg2576 mice was observed: in apoE4 mice, LepR
expression was significantly increased in young animals and decreased in
old animals, as compared to ApoE3 mice (Fig. 2E, P = 0.02 for young
mice; P = 0.04 for old mice). No expression of leptin was found in brain
tissue from apoE3 and apoE4 mice (data not shown).
Discussion
Several recent studies have focused on the involvement of leptin in AD,
but its role in the pathological processes is still not clear. Until now,
studies on the association between circulating leptin levels and AD have
shown opposite and paradoxical results. In a small case–control study,
leptin levels were observed to be low in patients with AD (Power et al.,
2001). Lieb et al. have reported that in normal individuals, elevated
plasma leptin levels are associated with lower incidence of dementia, AD
and larger brain volumes (Lieb et al., 2009). On the other hand,
Rajagopalan et al. reported that higher leptin plasma levels correlated
with lower brain volumes (Rajagopalan et al., 2012). Moreover, circu-
lating leptin may not adequately represent CSF leptin levels (Schwartz
et al., 1996), and, to our knowledge, the levels of leptin in CSF and its
association with AD pathology and progression have been investigated
only in a small cohort (Bonda et al., 2013).
In this study, we measured leptin levels in the CSF of 278 subjects
from the ADNI cohort. The leptin levels were correlated with the main
CSF biomarkers for AD, such as Ab1-42, p-tau or t-tau. As an association
between plasma leptin and hippocampal volume has been reported (Lieb
et al., 2009), we also explored the possibility of a relationship between
CSF leptin levels and hippocampal volume, independently of per cent
body fat. Noteworthy, our data showed no significant changes in CSF
leptin levels among controls, MCI-s, MCI-c and patients with AD. In a
linear regression analysis across all individuals, adjusting for age, gender,
diagnostic groups, MMSE, education and apoE genotype, the correlation
between hippocampal volume and leptin was found to be due to
differences in gender. CSF leptin levels were significantly higher in
women than in men. This difference observed is probably due to gender
differences in body fat, sex hormones and insulin levels (Ostlund et al.,
1996; Rosenbaum et al., 1996). When women and men were taken
separately, no correlation was found between leptin and hippocampal
volumes. Moreover, no correlation between leptin and CSF biomarkers
of AD was found.
As leptin regulates and triggers inflammation by means of actions on
its receptors and evidence suggest an involvement of leptin in the
upregulation of inflammatory cytokines [for review see (Paz-Filho et al.,
2013)], correlations between leptin and several inflammatory markers
levels were also measured. Among all the cytokines available in this
study, only IL-6R and IL-3 were found to correlate with leptin, although
these correlations disappeared after adjustment for age, gender,
diagnostic groups, MMSE, education and apoE genotype.
To better elucidate the cellular distribution of leptin in cerebral areas
involved in the disease, immunohistochemical analyses of hippocampus
and frontal cortex from patients with AD and controls were performed.
In control individuals, leptin staining was mainly located in neurons;
while in patients with AD, it was mainly present in reactive astrocytes.
This pattern was seen in hippocampus but not in frontal cortex areas.
Young and old Tg2576 mice were also analysed; the choice of different
ages reflects two stages of AD pathology, because amyloid plaques and
memory deficits are observed by 9 months of age in these mice. In old
Tg2576 mice brains, leptin was reduced in neurons when compared to
Wt old animals. Noteworthy, an increase of leptin staining in astrocytes
was also found in old Tg2576 mice, suggesting that Ab overproduction
induces a decrease of leptin in neurons and a relocalization of leptin
towards reactive astrocytes.
We next investigated the possibility of a direct effect of Ab1-42 on
leptin production and leptin signalling in the brain. Thus, leptin and LepR
expression levels were measured in primary cultures of astrocytes and
hippocampal neurons treated with Ab1-42 and in the hippocampus of
Tg2576 mice. Although there is some evidence for expression of leptin
mRNA in the brain (Morash et al., 1999) and in a neuroblastoma cell line
(Marwarha et al., 2011), we could not detect leptin expression in mice
brain (wt, Tg2576, apoE3 or apoE4), neither in astrocytes nor
hippocampal neurons from rat primary cultures, both in basal conditions
or after treatment with Ab1-42. Our results support the idea that leptin
detected in the brain comes from the periphery. Thus, leptin transport at
Table 3 Results of linear regression analyses for leptin and hippocampal volume
Standardized coefficient P-value
Hippocampal volume 0.024 0.676
Age (years) 0.068 0.213
Education (years) 0.094 0.084
Gender (0: female, 1: male) 0.468 <0.001
APOE4 category (0: negative, 1: positive) 0.009 0.874
Dependent variable is leptin and adjustment made for age, education, gender and
APOE ԑ4 category.
Alterations of leptin signalling in AD, S. Maioli et al. 3
ª 2014 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
the BBB, BBB integrity and LepR levels in brain cells would be key factors
for leptin levels and leptin signalling in brain. Leptin is transported across
the BBB by a saturable and unidirectional system (Hileman et al., 2002),
and impairment of leptin transport across the BBB has been reported in
obesity (Burguera et al., 2000), contributing to a leptin-resistant state
(Caro et al., 1996). This impairment has not been reported in AD,
(A)
(B)
Fig. 1 Alterations in leptin localization and leptin signalling in AD brains. (A) Leptin immunoreactivity in AD and control brains. (I–VI) Photomicrographs of sections DAB
stained with leptin showing different fields of the hippocampal formation (I,IV, III, VI, CA1 region and II, V granular layer) from control (I–III) and patient with AD (IV–VI). (VII–
XII) Confocal microscopy images of the frontal cortex from control (VII–IX) and patient with AD (X–XII) showing triple staining of leptin (red) and GFAP (green) antibodies and
DAPI (blue). (VII–XII, X–XII) Stacks of 11 and 7 confocal optical sections, respectively (step size: 1 lm). Scale bar (in XII): 50 lm in I–VI; 120 lm in VII–XII. Quantification of
astrocytes and neurons immunopositive for leptin in CA1 and frontal cortex of AD and control brains. Number of stained cells is given as percentage of total number of cells
(*P < 0.05). (B) Decrease of leptin signalling in hippocampus of AD brains. Immunoblots from hippocampal homogenates from CTL and patients with AD, using anti-p-LepR,
anti-LepR and anti-p-STAT3 antibodies. Data are shown as mean  standard error of mean of immunoreactivity (OD 9 area of the band) normalized by GAPDH levels. CTL
were used as reference. (*P < 0.05, **P < 0.01, ***P < 0.001, N = 4).
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(A)
(B)
(D)
(E)
(C)
Fig. 2 Alterations in leptin localization and leptin receptor expression in Tg2576 and apoE4 mice. (A) Leptin immunoreactivity in the brain of wild-type and Tg2576 mice.
Upper images: confocal microscopy field view of a hippocampus from young (7-month-old) Wt and old (15-month-old) Tg2576, showing the cellular distribution of anti-
leptin antibody (red) and anti-GFAP antibody (green). Lower images: representative images of CA1 region from young and old Wt and Tg2576 mice, respectively, showing
leptin immunoreactivity (red) in pyramidal neurons and astrocytes. Scale bars for the upper images 180 lm; for the lower images 50 lm. Quantification of astrocytes and
neurons immunopositive for leptin in the hippocampus of wild-type and Tg 2576. Number of stained cells is given as percentage of total number of cells (*P < 0.05, N = 4).
(B) Altered LepR expression levels in hippocampus of Tg2576 mice. LepR expression levels were analysed by real-time RT-PCR in hippocampus from young (5-month-old) and
old (24-month-old) Wt and Tg2576 mice. Data are presented as mean  standard error of mean. (*P < 0.05, N = 4). (C) Ab1-42 increases LepR expression levels in both
astrocytes and neurons. (A) Rat primary astrocytes and hippocampal neuronal cultures were treated with Ab1-42 and Abscr (0.5 lM) for 24 h. LepR expression levels were
analysed by real-time RT–PCR. Data are presented as mean  standard error of mean (***, P < 0.001). Three independent experiments, each in triplicate, were
performed.(D) Leptin immunoreactivity in apoE4 and apoE3 mice brain sections. Representative images of CA1 region and layer I-III of enthorinal cortex (EC) from apoE4 and
apoE3 mice showing triple staining of leptin (green) and GFAP (red, as glial marker) antibodies and DAPI (blue, as nuclear marker). Scale bar = 50 lm. Quantification of
astrocytes and neurons immunopositive for leptin in the hippocampus of apoE3 and apoE4. Number of stained cells is given as percentage of total number of cells
(*P < 0.05, N = 4). (E) Altered LepR expression levels in hippocampus of apoE4 mice. LepR expression levels were analysed by RT–PCR in hippocampus from young (6-
month-old) and old (16-month-old) apoE4 and apoE3 mice. Data are presented as mean  standard error of mean. (*, P < 0.05, N = 4).
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although it is suggested that the existence of a general BBB impairment
in the late and severe stages of the disease (Viggars et al., 2011) would
favour the permeability of leptin to the brain. However, this may not be
the case in early stages of AD, because differences in CSF leptin levels at
the early phases of AD progression were not found. At these early
phases, BBB integrity remains intact, as demonstrated in a subgroup of
CSF samples using albumin CSF/serum ratio (Supplementary Table S3).
Noteworthy, AD brains used for immunohistochemistry and immuno-
blotting analyses were from subjects with severe AD, which would result
in a more severe BBB impairment and consequently in increased leptin
levels in the brain.
We found that Ab1-42 treatment stimulates LepR synthesis in both
astrocytes and neurons, suggesting that leptin signalling might be
enhanced under Ab accumulation conditions. This result was further
confirmed in young Tg2576 mice, where an increase of LepR expression
was found in the hippocampus compared to Wt. This is in agreement
with previous work showing increased pSTAT3 levels in APP/PS1
transgenic mice before plaque formation (Wan et al., 2010). Treatment
with leptin has been shown to reduce plaque burden in young Tg2576
mice (Fewlass et al., 2004). At that age, prior to plaque formation,
Tg2576 animals already show BBB impairment (Ujiie et al., 2003), which
could facilitate leptin delivery into the brain. According to our findings,
these animals also have enhanced expression of LepR, which could
further contribute to the positive effects of leptin treatment. However, in
old Tg2576 mice, an opposite pattern with a significant decrease in LepR
expression was observed. This suggests the existence of a downregu-
lation of the signalling towards leptin resistance, which would question
the effectiveness of leptin therapy at that stage of the pathology. In
support of this, it has been reported that increased food intake causes
obesity and insulin resistance in these animals (Kohjima et al., 2010). It
has also been shown that acute treatment with Ab1-42 in hippocampal
neurons activates, while chronic treatment inhibits, STAT3 (Chiba et al.,
2009). Importantly, we found a decrease in pSTAT3 in hippocampus of
severe patients with AD, which is also in agreement with a previous
report (Chiba et al., 2009). Based on this evidence, it might be
suggested that Ab1-42 initially causes an enhancement of leptin
signalling, leading to leptin resistance over time.
Interestingly, apoE4 mice showed similar changes in leptin localization
and LepR synthesis to those seen in Tg2576 mice. In apoE4 mice, leptin
was also decrease in neurons and also more abundant in reactive
astrocytes, and LepR expression was increased in the hippocampus of
young animals but decreased in old animals, as compared to apoE3
mice. ApoE4 is a major risk factor for AD, but apoE4 mice do not show
Ab overproduction or plaque formation. Thus, a similar impairment of
leptin signalling is occurring independently of Ab, in an alternative
animal model of relevance for AD pathology. As Tg2576 mice, apoE4
mice have BBB disruption at the age of 9 months (Bell et al., 2012), and
signs of BBB impairment have been shown in humans carrying the apoE4
allele (Salloway et al., 2002). However, no reports have shown an
association between apoE4 and leptin resistance in humans.
The mechanisms by which Ab and apoE4 affect LepR expression are
unknown. Both molecules have been shown to cause inflammatory
responses, and LepR was shown to be upregulated in inflammatory
conditions, suchasLPSandTNFa treatments (Hsuchouet al., 2009). In fact,
animal models for human Ab overproduction or human apoE4 expression
showed enhanced inflammatory reactions in the brain including TNFa
generation and gliosis (Munch et al., 2003; Zhu et al., 2012). Thus, it may
be speculated that the initial upregulation of LepR could result from the
pro-inflammatory effects of Ab or apoE4. On the other hand, chronic
inflammation is known to cause leptin resistance (Martin et al., 2008).
In summary, no significant changes were observed in CSF leptin levels
in AD, at least in stages where the BBB remains intact, as compared to
controls. Animal models of Ab accumulation and apoE4 genotype show
a biphasic alteration in leptin signalling, with an early activation followed
by a downregulation of leptin receptors. This downregulation is also seen
in brains from individuals suffering of severe AD. These results suggest
that alteration in leptin signalling should be considered when studying
the putative neuroprotective effects of leptin in the disease. It is likely
that the beneficial effects of leptin would be limited to early, rather than
to late phases of AD.
Experimental procedures
Subjects
The study cohort includes 278 subjects: 88 controls (CTL), 63 subjects
with AD, 81 subjects with stable mild cognitive impairment (MCI-s) and
46 MCI subject that converted to AD within 18 month after baseline
(MCI-c) from the North American multicenter Alzheimer’s Disease
Neuroimaging Initiative (ADNI). Additional information about the ADNI
cohort, including inclusion criteria, can be found as supplementary data.
Magnetic resonance imaging (MRI) and cerebrospinal fluid
(CSF)
Both MRI and CSF data were downloaded from the ADNI website (www.
loni.ucla.edu/ADNI). The description of CSF collection and data acqui-
sition of the ADNI study can be found as supplementary data. MRI data
from 1.5 T scanners were used with data collected from a variety of MR
systems with protocols optimized for each type of scanner. The MRI
protocol included a high-resolution sagittal 3D T1-weighted MPRAGE
volume (voxel size 1.1 9 1.1 9 1.2 mm3) acquired using a custom pulse
sequence specifically designed for the ADNI study to ensure compatibility
across scanners. Full brain and skull coverage was required for the MRI
data sets and detailed quality control carried out on all MR images
according to previously published quality control criteria (Simmons et al.,
2011).
Hippocampal segmentation
Volumetric segmentation of the hippocampus was performed using the
FREESURFER software package, version 5.1.0 (http://surfer.nmr.mgh.har-
vard.edu/) (Fischl et al., 2002). The procedure automatically assigns a
neuroanatomical label to each voxel in an MRI volume based on
probabilistic information automatically estimated from a manually
labelled training set. All hippocampal volumes (left and right side
averaged) from each subject were normalized by the subject’s intracra-
nial volume (Westman et al., 2013), which is estimated based on an
affine transform in FreeSurfer. This segmentation approach has been
used for multivariate classification of Alzheimer’s disease and healthy
controls (Westman et al., 2011) and biomarker discovery (Thambisetty
et al., 2010).
Brain tissue, immunohistochemistry and immunoblotting
Brain material was obtained from the Brain Bank at Karolinska Institutet
(Sweden). Immunohistochemistry was performed on hippocampus and
frontal cortex from 4 brains from patients with definite AD (two males
and two females 75–86-year-old) and 4 aged-matched controls (two
females and two males, 66–87-year-old). For immunoblotting, 4
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additional hippocampal samples from AD brains (males, 74–98-year-old)
and 3 controls (males, 56–71-year-old) were used. DAB immunostaining,
immunofluorescence and immunoblotting were performed as described
previously (Akterin et al., 2006; Maioli et al., 2012). The list of primary
antibodies is in supplementary Table 1 (Table S1). Estimation of the
number of cells immunopositive for leptin was performed using
NEUROLUCIDA NEURON Tracing Software (MBF Bioscience). Three slides per
mice and human brain were analysed, and number of stained cells is
given as percentage of total number of cells.
Transgenic mice
Five-month-old (young) and 2-year-old (old) female transgenic mice
(Tg2576) overexpressing human amyloid precursor protein carrying the
Swedish mutation (K670N/M671L) under the genetic mixed hybrid
background C57BL/6/SJL and wild-type littermates (Wt) were used. Six-
month-old (young) and 16-month-old (old) male hApoE Target Replace-
ment (TR) mice expressing human apoE3 and apoE4, under the control
of the murine apoE regulatory sequences and on a C57BL/6J background
were used (Maioli et al., 2012). Four animals per genotype and age were
used. All mice were kept under controlled temperature (21 °C  1) and
humidity (55  5%) on a 12-h light–dark cycle, and food/water was
provided ad libitum. Experimental procedures were conducted in
accordance with the European regulation and approved by the Ethical
Committees of University of Navarra and Bologna.
Rat primary culture and real-time RT–PCR
Cerebellar and hippocampal tissue from 16-day-old Sprague–Dawley rat
embryos was homogenized in serum-free NeuroBasal medium with B27
supplement (2%). Astrocytes were serum-starved for 24 h before
treatment. Ab1-42 (Sigma-Aldrich, MO, USA) and Ab1-42 scrambled
(Abscr) (rPeptide, GA, USA) were prepared as previously described (Chiba
et al., 2009) and used at 0.5 lM for 24 h. Ethical consent was received
from the regional ethical committee of Karolinska Institutet. RNA
extraction and real-time RT–PCR were performed as previously described
(Mateos et al., 2011), using PCR Master Mix and TaqMan Gene
Expression Assays (for rats: LepR Rn01433205_m1, GAPDH
Rn01775763_g1; for mice, LepR Mm00440181_m1, GAPDH Catalogue
Number 4352932E) (Life Technologies, CA, USA).
Statistical analysis
One-way ANOVA was used to compare differences between mean levels
of variables in the four groups, followed by HSD Tukey’s post hoc
analysis. Bivariate correlation test was performed to calculate the
correlation between pairs of variables, and Pearson correlation coeffi-
cient was reported. Linear regression analysis was utilized to calculate
the adjusted correlation for covariates/confounders variables. Mann–
Whitney test was used for immunoblotting. For quantification of the
immunohistochemistry, Mann–Whitney and Kruskall–Wallis test were
used. Unpaired t-test or one-way ANOVA followed by HSD Tukey’s post
hoc analyses was used for RT–PCR experiments. A P-value < 0.05 was
considered statistically significant.
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